Parataxis Korea Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 21

Employees

  • Stock Symbol
  • 288330

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.28
  • (As of Tuesday Closing)

Parataxis Korea General Information

Description

Parataxis Korea Inc is a Bitcoin treasury platform. It is an institutionally backed Bitcoin treasury company, which is composed of professionals with deep experience across institutional capital markets, digital assets, risk management, and regulatory policy.

Contact Information

Formerly Known As
Bridge Biotherapeutics
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Corporate Office
  • Suite 303, Cs Tower, 58, Pangyo-ro 255 beon-gil
  • Bundang-gu
  • Seongnam, Gyeonggi 13486
  • South Korea
Primary Industry
Other Financial Services
Other Industries
Asset Management
Specialized Finance
Stock Exchange
KRX
Corporate Office
  • Suite 303, Cs Tower, 58, Pangyo-ro 255 beon-gil
  • Bundang-gu
  • Seongnam, Gyeonggi 13486
  • South Korea

Parataxis Korea Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Parataxis Korea Stock Performance

As of 07-Apr-2026, Parataxis Korea’s stock price is $0.28. Its current market cap is $29.2M with 106M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.28 $0.28 $0.26 - $6.52 $29.2M 106M 1.03M -$0.31

Parataxis Korea Financials Summary

As of 30-Jun-2026, Parataxis Korea has a trailing 12-month revenue of $1.1M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 28,994 42,175 104,224 36,706
Revenue 1,098 6 2 76
EBITDA (21,154) (22,061) (13,730) (32,043)
Net Income (20,487) (21,779) (14,479) (32,369)
Total Assets 37,508 49,188 22,738 26,556
Total Debt 2,260 2,939 1,782 2,752
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Parataxis Korea Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Parataxis Korea‘s full profile, request access.

Request a free trial

Parataxis Korea Patents

Parataxis Korea Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025254295-A1 Pharmaceutical composition comprising autotaxin inhibitor as active ingredient for preventing or treating calcification-related disease Pending 07-Jun-2024
WO-2024072178-A1 Compound for targeted protein degradation, and use thereof Inactive 30-Sep-2022
US-20230330112-A1 Composition and treatment for cancer with mutations Inactive 15-Apr-2022
WO-2023201024-A1 Composition and treatment for cancer with mutations Inactive 15-Apr-2022
EP-4313969-A1 N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof Inactive 02-Apr-2021 C07D401/14
To view Parataxis Korea’s complete patent history, request access »

Parataxis Korea Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Parataxis Korea Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Parataxis Korea‘s full profile, request access.

Request a free trial

Parataxis Korea Investments & Acquisitions (3)

Parataxis Korea’s most recent deal was a PIPE with Shinsyway for . The deal was made on 06-Jan-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Shinsyway 06-Jan-2026 PIPE Systems and Information Management
Parataxis Korea (Local Bitcoin Mining Facility in the United States) 24-Sep-2025 Corporate Asset Purchase Buildings and Property
Ellips Diagnostics 28-Apr-2023 Merger/Acquisition Other Commercial Products
To view Parataxis Korea’s complete investments and acquisitions history, request access »

Parataxis Korea ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Parataxis Korea’s complete esg history, request access »

Parataxis Korea FAQs

  • When was Parataxis Korea founded?

    Parataxis Korea was founded in 2015.

  • Where is Parataxis Korea headquartered?

    Parataxis Korea is headquartered in Seongnam, South Korea.

  • What is the size of Parataxis Korea?

    Parataxis Korea has 21 total employees.

  • What industry is Parataxis Korea in?

    Parataxis Korea’s primary industry is Other Financial Services.

  • Is Parataxis Korea a private or public company?

    Parataxis Korea is a Public company.

  • What is Parataxis Korea’s stock symbol?

    The ticker symbol for Parataxis Korea is 288330.

  • What is the current stock price of Parataxis Korea?

    As of 07-Apr-2026 the stock price of Parataxis Korea is $0.28.

  • What is the current market cap of Parataxis Korea?

    The current market capitalization of Parataxis Korea is $29.2M.

  • What is Parataxis Korea’s current revenue?

    The trailing twelve month revenue for Parataxis Korea is $1.1M.

  • What is Parataxis Korea’s annual earnings per share (EPS)?

    Parataxis Korea’s EPS for 12 months was -$0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process